News for RNLX Stock

Commencement of trading on OTCQB in the United States Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination Medicare Issues Final Coverage Determination for kidneyintelX.dkd Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024 Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15 Renalytix Announces Financing with Expected Size of up to $4 Million KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD) Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024 Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024 Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14 US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix Renalytix Reports Full Year Fiscal 2023 Results Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28 Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd Renalytix Announces Middle East Distribution Agreement with Vector Pharma Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023 Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9 Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes New Published Real-World Evidence Shows KidneyIntelX™ Utility Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30 Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Renalytix announces a c.$20.3 million private placement Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023 Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30 Renalytix to Present at Stifel Healthcare Conference Renalytix Reports Full Year Fiscal 2022 Results Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31 KidneyIntelX Clinical Utility and Health Economics Validated in Multiple Data Releases at American Society of Nephrology Renalytix Announces Change to Board of Directors Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022 Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30 1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients Renalytix to Present at 42nd Annual William Blair Growth Stock Conference KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort Renalytix Announces Two Data Presentations on KidneyIntelX™ at American Diabetes Association 82nd Scientific Sessions® Renalytix plc successful completion of $30.0 million financing package Renalytix plc Issue of shares Renalytix announces a $30.0 million financing package Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022 Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31 Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform KidneyIntelX™ Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of Care Renalytix to Present at Cowen 42nd Annual Health Care Conference Renalytix to Appoint Timothy Scannell to Board of Directors Renalytix to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Positive Study Results Published for KidneyIntelX™ in Monitoring Patient Response to New Drug Therapy Singing River Health System and Renalytix Join Forces to Improve Kidney Health on the Mississippi Gulf Coast Renalytix Appoints Jean M. Casner as Chief Human Resources Officer Renalytix to Present at 40th Annual J.P. Morgan Virtual Healthcare Conference American Diabetes Association and Renalytix Partner to Prioritize Kidney Health in Type 2 Diabetes Population Renalytix Reports Financial Results for First Quarter of Fiscal Year 2022 Renalytix to Report First Quarter Fiscal Year 2022 Financial Results on December 7 Renalytix Convenes Expert Panel at VA Healthcare Summit St. Joseph’s Health and Renalytix Partner to Advance Value-Based Kidney Health in New York Renalytix Reports Full Year Fiscal 2021 Results Renalytix to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results on October 21 Renalytix Launching KidneyIntelX in Veterans Health Administration Hospitals Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX™ Enabled Health Care Model Renalytix to Present at the 2021 Wells Fargo Virtual Healthcare Conference Renalytix Appoints Daniel J. Levangie to its Board of Directors Payer Budget Impact Analysis Projects Significant Savings from KidneyIntelX™ Testing at Primary Care Level Renalytix Appoints Ann Berman to its Board of Directors Renalytix to Present at the 41st Annual Canaccord Genuity Global Growth Conference Renalytix Appoints Joseph Hutson Vice President of Global Quality and Regulatory KidneyIntelX™ Enables Monitoring of SGLT2 Inhibitor Therapy Response and Corresponding Risk Reduction Over Time Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021 Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update Leadership Additions Announced to Support Expanding US Government and Healthcare Provider KidneyIntelX Deployment Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care Kantaro's Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order Atrium Health, Wake Forest Baptist Health, Wake Forest School of Medicine and Renalytix Partner to Advance Kidney Health Kantaro's COVID-SeroKlir Antibody Test Named As A Finalist For Fast Company's 2021 World Changing Ideas Awards U.S. General Services Administration Grants 10-Year Governmentwide Contract for RenalytixAI KidneyIntelX Testing KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular Assessment Study (CANVAS) RenalytixAI and Joslin Diabetes Center Build on Proprietary Kidney Biomarker Portfolio for KidneyIntelX Platform Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure Update on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics Renalytix AI plc Issue of Shares Under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights RenalytixAI Reports Financial Results for Second Quarter of Fiscal Year 2021 The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health RenalytixAI to announce Financial Results for six and three months ended December 31, 2020 American Society of Nephrology and Renalytix to Co-Host Virtual Capital Markets Day for Kidney Health Kantaro Biosciences Named to Fast Company's Annual List of the World's Most Innovative Companies for 2021 and Ranked First in the Joint Ventures Category FDA Adds Kantaro's Semi-Quantitative COVID-19 Antibody Test to Revised Emergency Use Authorization for Convalescent Plasma Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America NKF and RenalytixAI Partner to Improve Management of Early Stage Kidney Disease Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitative COVID-19 Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies EKF and Kantaro Partner to Market Quantitative COVID-19 Antibody Testing in the UK and Europe CE Mark Approval Granted to Kantaro COVID-SeroKlir and COVID-SeroIndex Quantitative Antibody Test Kits RenalytixAI To Announce Financial Results for Full Year Ended June 30, 2020 and Provide Corporate Update RenalytixAI Receives California Commercial Laboratory Certification RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing with Mount Sinai Health System RenalytixAI Files Submission Seeking U.S. FDA Clearance of KidneyIntelX RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease RenalytixAI Announces Closing of Global Offering and Resulting Total Voting Rights RenalytixAI Announces Launch of Global Offering and Application to List on the Nasdaq Global Market RenalytixAI Announces Pricing of Global Offering and Approval to List on the Nasdaq Global Market